Maintenance therapy for B-Chronic lymphocytic leukemia

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 1, 2011, Pages 22-31

  O'Brien, Susan ^a   Kay, Neil E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mayo Clinic   (United States)

Author keywords

Chronic lymphocytic leukemia; Immunomodulatory drugs; Lenalidomide; Maintenance therapy

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CURCUMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIGALLOCATECHIN GALLATE; FLUDARABINE; GCS 100; GENISTEIN; LENALIDOMIDE; PECTIN; PHENETHYL ISOTHIOCYANATE; PLACEBO; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LYMPHOCYTOSIS; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR FLARE; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CATECHIN; CURCUMIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THALIDOMIDE;

EID: 79951479083     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
3. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol. 2007;25:793-798.
4. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet. 2007;370:230-239.
5. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405-411.
6. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
7. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
8. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
9. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756-1765.
10. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. Lancet. 2010;376:1164-1174.
11. Keating MJ, Wierda WG, Tam CS, et al. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 2381.
12. O'Brien S, Kantarjian H, Beran M, et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995;86:1298-1300.
13. Zinzani PL, Bendandi M, Magagnoli M, et al. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Eur J Haematol. 1997;59:82-88.
14. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.
15. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112:119-128.
16. Wendtner C-M, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission- experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093-1101.
17. Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma. 2004;45:711-714.
18. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607-1614.
19. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008.
20. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010; 28:Abstract 8004.
21. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-1552.
22. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348-3352.
23. Furman RR, Leonard JP, Allen SL, et al. Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabinerelapsed and refractory CLL. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:Abstract 6640.
24. Laurenti L, Piccioni P, Tarnani M, et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk Res. 2007;31:253-256.
25. Kay NE, Shanafelt TD, Call TG, et al. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:588-592.
26. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009;106:6250-6255.
27. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
28. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618-621.
29. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427-2437.
30. James DF, Choi MY, Betty M, et al. Primary chronic lymphocytic leukemia (CLL) cells survival support from NLC and SDF-1a (CXCL-12) in vitro and the effect of lenalidomide (LEN). J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 7070.
31. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650-4657.
32. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
33. Chanan-Khan A, Miller KC, Whitworth A, et al. Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymphoma. 2007;48(suppl 1):S166.
34. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2010. Epub ahead of print.
35. Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
36. Chen CI, Paul H, Xu W, et al. Safety and efficacy of slow dose-escalation of lenalidomide for frontline treatment in chronic lymphocytic leukemia (CLL)- results of a phase II study. Haematologica. 2009;94(suppl 3):Abstract 10.29.
37. Badoux X, Wierda WG, O'Brien SM, et al. A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28(15 suppl):Abstract 6508.
38. San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Longer duration of treatment and maintenance of best response with lenalidomide and dexamethasone prolongs overall survival in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 3702.
39. Dimopoulos MA, Hussein M, Swern AS, Weber D. Full dose of lenalidomide for 12 months followed by a lower maintenance dose improves progression-free survival in patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 2874.
40. Béliveau R, Gingras D. Role of nutrition in preventing cancer. Can Fam Physician. 2007;53:1905-1911.
41. Cvorovic J, Tramer F, Granzotto M, et al. Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells. Arch Biochem Biophys. 20101;501:151-157.
42. Fernandes I, Faria A, Azevedo J, et al. Influence of anthocyanins, derivative pigments and other catechol and pyrogallol-type phenolics on breast cancer cell proliferation. J Agric Food Chem. 2010;58:3785-3792.
43. Feng R, Wang SY, Shi YH, et al. Delphinidin induces necrosis in hepatocellular carcinoma cells in the presence of 3-methyladenine, an autophagy inhibitor. J Agric Food Chem. 2010;58:3957-3964.
44. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer-a mini review. J Pharm Pharmacol. 2008;60:139-144.
45. Powolny AA, Singh SV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett. 2008;269:305-314.
46. Ahmad A, Sakr WA, Rahman KM. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets. 2010;11:652-666.
47. Sharma C, Sadrieh L, Priyani A, et al. Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells. Cancer Epidemiol. 2010 Oct 16. [Epub ahead of print]
48. Kim MJ, Kim SH, Lim SJ. Comparison of the apoptosis-inducing capability of sulforaphane analogues in human colon cancer cells. Anticancer Res. 2010; 30:3611-3619.
49. Kanematsu S, Uehara N, Miki H, et al. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res. 2010;30:3381-3390.
50. Resveratrol monograph. Altern Med Rev. 2010;15:152-158.
51. Billard C, Izard JC, Roman V, et al. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma. 2002;43:1991-2002.
52. Rop O, Mlcek J, Jurikova T. Beta-glucans in higher fungi and their health effects. Nutr Rev. 2009;67:624-631.
53. Péter G, Károly V, Imre B, János F, Kaneko Y. Effects of lentinan on cytotoxic functions of human lymphocytes. Immunopharmacol Immunotoxicol. 1988; 10:157-163.
54. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804-3816.
55. Lee YK, Bone ND, Strege AK, et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004;104:788-794.
56. Higashi N, Kohjima M, Fukushima M, et al. Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. J Lab Clin Med. 2005;145:316-322.
57. Aznar S, Fernández-Valerón P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004;206:181-191.
58. Sakata R, Ueno T, Nakamura T, et al. Green tea polyphenol epigallocatechin- 3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol. 2004;40:52-59.
59. Kuo PL, Lin CC. Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fasmediated pathways. J Biomed Sci. 2003;10:219-227.
60. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009;15: 1250-1258.
61. Lamy S, Gingras D, Béliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 2002;62:381-385.
62. Lesnick C, Kay NE, LaPlant B, Shanafelt TD. The green tea extract EGCG demonstrates synergist activity against CLL B-cells when combined with fludarabine and chlorambucil. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 3452.
63. Shanafelt TD, Lee YK, Call TG, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006;30:707-712.
64. Shanafelt TD, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009;27:3808-3814.
65. Shanafelt TD, Call T, Zent CS, et al. Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL). J Clin Oncol. 2010;28(15 Suppl):Abstract 6522.
66. Everett PC, Meyers JA, Makkinje A, et al. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007;82:23-30.
67. Angelo LS, Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin Cancer Res. 2009;15:1123-1125.
68. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.
69. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 2006;10:241-252.
70. Carew JS, Nawrocki ST, Xu RH, et al. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia. 2004;18:1934-1940.
71. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003;278:37832-37839.
72. Oltra AM, Carbonell F, Tormos C, et al. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med. 2001;30:1286-1292.
73. Hileman EO, Liu J, Albitar M, et al. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol. 2004;53:209-219.
74. Trachootham D, Zhang H, Zhang W, et al. Effective elimination of fludarabine- resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008;112:1912-1922.
75. Uckun FM, Messinger Y, Chen CL, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19- directed tyrosine kinase inhibitor. Clin Cancer Res. 1999;5:3906-3913.
76. Mansour A, Chang VT, Srinivas S, et al. Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein. Cancer Immunol Immunother. 2007;56:501-514.
77. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65:8350-8358.
78. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94:1854-1862.
79. Grous JJ, Redfern CH, Mahadevan D, Schindler J. GCS-100, a galectin-3 antagonist, in refractory solid tumors: a phase I study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24(18 suppl):Abstract 13023.
80. Cotter F, Smith DA, Boyd TE, et al. Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(15 suppl):Abstract 7006.